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The interaction between Clq and immune complexes is inhibited by 1-anilino-8-naphthalenesulfonate 
(ANS) in the concentration range of 2-4 mM. ANS binds to Clq with a 20-fold higher afl]nity than to 
IgG [(1986) Mol. Immunol. 23, 39-44] and therefore it is possible to label only Clq with ANS in the presence 
of lgG. Under such conditions no inhibition is observed. Addition of monomer IgG to a solution of C lq- 
bound ANS did not significantly alter the fluorescence of the ANS. However when oligomeric IgG was 
added there was a 2-fold increase in fluorescence over the same lgG concentration range. When Clq was 
pretreated with diethylpyrocarbonate there was little change in the fluorescence when IgG oligomers were 
added to Clq:ANS solutions. These results suggest hat Clq undergoes conformational changes upon 
binding to lgG oligomers. 
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1. INTRODUCTION 
The first component of the classical complement 
pathway, C1, is a complex of three glycoproteins; 
an immunoglobulin recognition unit, Clq, and a 
CaZ+-dependent tetramer of two zymogens, 
Clr2Clsz [1]. The activation of the classical com- 
plement pathway is initiated by binding of C1, via 
Clq, to aggregated lgM or IgG [2]. This process is 
followed by auto-catalytic activation of Clr  to give 
Clr [3]. The proteolytic activity of Clr  is then 
directed against Cls, which in turn becomes a 
serine protease, responsible for activation of com- 
plement proteins C4 and C2 [2]. 
The trigger for auto-catalytic activation of Clr  
remains unclear, but it has been suggested that this 
process occurs as a consequence of altered interac- 
tions between Clq and Clr, caused by structural 
changes within Clq attendant upon its binding to 
aggregated immunoglobulin [4]. 
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In an attempt to detect structural changes within 
Clq upon binding to aggregated lgG, we have ex- 
ploited the fact that the fluorescent probe, 
1-anilino-8-naphthalenesulfonate (ANS) binds to 
Clq with 20-fold higher affinity than to IgG [5]. 
The data presented below show that there is a 
change in the fluorescence of Clq-bound ANS 
when the protein binds to oligomers of IgG. Thus, 
it would seem that there is a structural change in 
Clq when it binds to lgG, and this change may be 
related to the process of C1 activation, 
2. MATERIALS AND METHODS 
2.1. Materials 
ANS (Mg salt) was obtained from Pierce 
(Rockford, IL) and diethylpyrocarbonate was 
from Sigma. Human C1 q was purified from serum 
and labelled with lzsI, using lactoperoxidase, by 
the procedures of Tenner and co-workers [6]. Anti- 
ovalbumin rabbit IgG and immune complexes 
(prepared at the equivalence IgG : ovalbumin ratio) 
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were obtained as in [71. Human IgG was prepared 
as in [8]; 250 mg of lgG was chemically crosslinked 
by dithiobis(succinimidylpropionate), with a 
crosslinker:lgG ratio of 1.8:1 (tool/tool), as in 
method B of [9]. The IgG oligomers were frac- 
tionated by gel filtration over Sephacryl S-300, 
equilibrated with 0.01 M phosphate, 0.15 M NaCI, 
pH 7.2. Samples containing predominantly IgG 
trimers and tetramers were pooled and stored at 
4°C prior to use. Such oligomers have been shown 
to be stable for up to 2 months at -70°C [9]. 
Samples containing monomeric IgG were treated 
similarly. 
2.2. Methods 
The immunoglobulin binding function of C lq  
was inactivated by treating the protein with 
diethylpyrocarbonate as in [10]. The binding of 
lZSl-labelled Clq to immune complexes was 
measured using the methods of [7]. The 
fluorescence of protein-bound ANS was measured 
at 490 _+ 5 nm, following excitation at 390 _+ 5 nm, 
using an Aminco SPF-500 spectrofluorimeter, with 
the cell-holders thermostatted at 37°C. 
3. RESULTS AND DISCUSSION 
3.1. Inhibition of Clq binding to immune 
complexes by ANS 
The data shown in fig.1 indicate that ANS in- 
hibits the binding of 125I-labelled Clq to immune 
complexes over the concentration range 2-4 mM. 
There have been several reports (e.g. [11]) that 
commercial ANS preparations may be con- 
taminated with bis-ANS, which may have a far 
higher affinity for proteins than ANS. This com- 
plication does not seem relevant in this case, 
because the ANS used in these experiments was 
pure as judged by high pressure liquid 
chromatography. A single absorbance peak at 
340 nm was seen when samples of ANS, in 0.05 M 
NH4HCO3, pH 7, were applied to an LKB C-18 
reverse phase column, developed with a gradient o 
100% methanol. 
We have previously reported that ANS is a com- 
petitive inhibitor, with respect to Clq,  of the 
C lq : lgG interaction [t2]. However, we have since 
shown [13] that it is not possible to draw such con- 
clusions from such inhibition data, without in- 
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Fig.1. Inhibition of the Clq:lgG interaction by ANS. 
The percentage of input ~ZSl-labelled C 1 q (0.2/~g. ml- ~, 
3 × 105 cpm.,ag ~), bound to immune complexes 
(100/~g.ml -~, in 0.05 M Tris-Cl, 0.1 M NaC1, 0.15o70 
(w/v) gelatin, pH 7.2) at the indicated ANS 
concentrations was determined by the methods of [7]. 
dependent direct measurements of the binding of 
the inhibitor to both proteins. 
In this context, Alcolea and co-workers [5] have 
shown that ANS binds to Clq with approx. 20-fotd 
higher affinity than to IgG. They concluded from 
this that it was probable that the documented [12] 
inhibition of the C lq : IgG interaction by ANS 
arose from binding of ANS to Clq. However, the 
data of fig.1 show that ANS inhibits this interac- 
tion in the miltimolar range; at these concentra- 
tions of ANS the high affinity binding sites on 
both IgG and Clq detected by Alcolea and co- 
workers would be completely saturated with ANS. 
Thus, it would appear that the inhibition of the 
C lq : IgG interaction arises from relatively weak 
interactions of one or both of the proteins with 
ANS; it does not seem possible to deduce which is 
involved from the ANS binding data reported by 
Alcolea and co-workers. 
3.2. Conformational changes in Clq upon binding 
to IgG 
ANS binds to Clq with an affinity constant of 
2 × 106 M -l, and to IgG with an affinity constant 
of 9 x 10 4 M -1 [5]. It would be expected that addi- 
tion of monomer IgG to a solution of Clq-bound 
ANS should have no effect on the fluorescence of 
the sample, because, firstly, monomer IgG binds 
to Clq with low affinity [14], and, secondly, a ma- 
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jority of the ANS molecules will remain bound to 
their high affinity Clq binding sites. 
The data shown in fig.2 are consistent with this 
prediction, in that, although ANS was able to bind 
to monomer IgG in the absence of Clq tias judged 
by an increase in ANS fluorescence with increasing 
IgG concentration), there was little change in the 
fluorescence of the samples when monpmer lgG 
was added to ANS in the presence of Clq.  
However, when oligomeric IgG was added to 
samples of Clq-bound ANS there was a 2-fold 
increase in their fluorescence, over thesame lgG 
concentration range (fig.3). Evidence that this 
change was a consequence of an IgG: C lq  interac- 
tion was obtained when the effects o f  adding 
oligomeric IgG to Clq which had been pretreated 
with diethylpyrocarbonate w re exami0ed. This 
reagent has been shown to inactivate specifically 
the immunoglobulin recognition sites o( Clq, by 
modification of histidine residues [10]. The data in 
fig.3 show that, firstly, pretreatmcnt of Clq with 
diethylpyrocarbonate did not lead to a difference 
in the fluorescence of protein-bound ANS, and 
secondly, there was little change in the 
fluorescence of ANS bound to diethvlpyrocar- 
bonate-treated Clq upon addition of oiigomeric 
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Fig.2. The fluorescence of ANS (0.2 ,aM) inthe presence 
(O) and absence (o) of 0.1 mg-mt -~ f.qq at the 
indicated monomeric IgG concentrations was 
determined as in section 2.2. The error bars indicate the 
extreme values of fluorescence noted over a l-min 
observation period for each IgG concentration. 
Experiments were carried out twice. 
IgG. Therefore it would appear that the changes in 
ANS fluorescence with unmodified Clq arose 
from structural changes in Clq upon binding to 
aggregated IgG. 
Alcolea and co-workers [5] have shown that  
ANS binds to the globular head regions of C lq .  
Thus, our data imply that the binding o f  
oligomeric IgG to Clq leads to changes in these 
sections of the molecule. The enhancement of the 
fluorescence of ANS attendant upon its binding to 
proteins has generally been interpreted as arising: 
from decreased polarity of the environment o f  
protein-bound ANS. Hence, the binding o f  
oligomeric lgG to Clq may lead to alterations in 
the tertiary structure of hydrophobic sections 
within the globular heads of Clq. This conclusion 
should be viewed with some caution, however, in 
the light of the work of Weber and co-workers 
[15], who showed that changes in the f luorescence 
of protein-bound ANS do not always result f rom 
alterations in the polarity of its environment. 
The above data, together with the demonstra-  
tion of neoantigens in Clq after its binding to im-  
mune complexes [4], do not necessarily bear on the  
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Fig.3. The fluorescence of ANS (0.2,aM): in the 
presence of 0.1 mg.m1-1 native Clq (co); 0.1 mg.ml -1  
Clq which had been pretreated with 0.2 mM 
diethylpyrocarbonate for 15 rain (o); and in the absence 
of Clq (i); at the indicated oligomeric IgG 
concentrations was determined as in section 2.2. The  
error bars indicate the extreme values of fluorescence 
noted over a 1-min observation period for each IgG ~ 
concentration. Experiments were carried out twice. 
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question of the trigger for activation of Clr and 
Cls upon binding of the C1 complex to aggregated 
lgG. Clr and Cls bind to the collagenous regions 
of Clq, and it remains to be shown that the struc- 
tural changes occurring in the Clq molecule upon 
its binding to IgG extend from the globular heads 
to the Clr2Cls2 binding site. 
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